Mustang Bio, Inc. filed a preliminary proxy statement on November 20, 2026, calling stockholders to a virtual Annual Meeting on December 21, 2026, where shareholders will vote on a proposed reverse stock split, director elections, and other matters.

Key Highlights

  • Annual Meeting date: December 21, 2026, at 10:00 a.m. Eastern Time, to be held virtually.
  • Reverse stock split proposed: Stockholders will vote on a certificate amendment authorizing a reverse split of issued and outstanding common stock within a range of 1-for-5 to 1-for-30, with the exact ratio to be set by the Board.
  • Nasdaq compliance purpose: According to the filing, the primary purpose of the reverse split is to regain compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
  • Seven directors up for election: Stockholders will vote to elect seven directors, each for a one-year term.
  • Auditor ratification: KPMG LLP is nominated for ratification as independent registered public accounting firm for the year ending December 31, 2026.
  • Record date: Only stockholders of record as of the close of business on November 17, 2026, are entitled to vote.

Mustang Bio's Proposed Reverse Split and 2026 Annual Meeting Agenda

Mustang Bio, Inc., a biopharmaceutical company headquartered at 95 Sawyer Road, Suite 110, Waltham, Massachusetts, filed a preliminary proxy statement with the SEC on November 20, 2026, in connection with its 2026 Annual Meeting of Stockholders. The filing is a Schedule 14A submitted by the registrant and is designated as a preliminary proxy statement subject to completion. Manuel Litchman, M.D., serves as the company's President, Chief Executive Officer, and Interim Chief Financial Officer, and signed the stockholder letter accompanying the filing.

The most consequential proposal before stockholders, according to the filing, is Proposal Four: approval of a form amendment to the company's Amended and Restated Certificate of Incorporation to effect a reverse stock split. The filing states that the split ratio would fall within a range of 1-for-5 to 1-for-30, with the Board authorized to determine the exact ratio at its discretion. The filing identifies the primary purpose as regaining compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company's shares are listed on NASDAQ:MBIO.

Beyond the reverse split vote, the meeting agenda includes the election of seven directors each serving a one-year term, an advisory (say-on-pay) vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor for the fiscal year ending December 31, 2026. Stockholders may submit questions and vote online during the virtual meeting. Proxy authorization, as stated in the filing, extends to Manuel Litchman, M.D. and/or Peter Carney or their designees.

What Was Disclosed

Mustang Bio filed a preliminary Schedule 14A proxy statement on November 20, 2026, noticing a December 21, 2026, virtual Annual Meeting. The filing presents five agenda items, with a proposed reverse stock split in the range of 1-for-5 to 1-for-30 being the principal corporate action requiring stockholder approval.